Psychedelika als Medikamente: aktueller Stand




Matthias E. Liechti Clinical Pharmacology University Hospital Basel Switzerland


Pharmazeutische Gesellschaft Basel, 30.11.2023



Psychedelic Clinical Trials



Conditions being investigated





Why psychedelics?






Spravato (esketamine) () 10 mL Multi- Dose NDC 484.9 10 mL Multi- Dose NDC 484.9 Ketamine HCI Injection, USP 500 mg per 10 mL 500 mg/mL) For dow intra-resease or intramedua to dow intra-resease


- Little innovation & low efficay of classic antidepressants
- Ketamine acts rapidly but not sustained
- Electroconvulsive therapy (low acceptance)
- \rightarrow Psychedelics may act rapidly and sustained according first studies
- Legalization/commercialization of (medical) cannabis





Holze et al. 2021 Neuropsychopharmacology 46: 537-544


The 5-HT_{2A} receptor antagonist Ketanserin reverses the acute LSD response




Becker et al. 2022 Int J Neuropsychopharmacol doi: 10.1093/ijnp/pyac075



Psychedelics promote plasticity by directly binding to BDNF receptor TrkB



LSD and psilocybin bind to TrkB, the receptor for BDNF with 1000-fold higher affinities than those of other antidepressants.




Psychedelic-induced neuroplasticity depends on TrkB and BDNF, but not 5-HT2A activation


Spines per 15 µm

Mollner et al. 2023 Nat Neurosci


BAG Ausnahmebewilligungen für die beschränkte medizinische Anwendung




3,4-Methylenedioxymethamphetamine (MDMA)



Oxytocin in response to MDMA in diabetes insipidus




MDMA reduces PTSD symptoms in phase 3 study



Mitchell 2021 Nature Medicine 27:1025-33

Psilocybin

- 1958 erstmals in Basel aus psilocybe mexicana (ψιλός kybē; Zauberpilz) extrahiert und auch synthetisch hergestellt
- Das heute am häufigsten in Patienten untersuchte Psychedelikum






Psilocybe mexicana



Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression




N=233; Psilocybin 25 mg vs. 10 mg vs. 1 mg

COMPASSION Navigating Mental Health Pathways N Engl J Med 2022;387:1637-48.


The NEW ENGLAND JOURNAL of MEDICINE

Psilocybin versus Escitalopram for Depression



RCT, major depression, N=59, two doses of psilocybin 25 mg or two doses of psilocybin 1 mg plus daily escitalopram, Quick Inventory of Depressive Symptomatology at 6 wks

Acute experience associated with long-term effects



51 cancer patients with depression/anxiety; 1/3 or 22/30 mg/70 kg of **psilocybin**, cross-over at 5 wks.


Griffiths et al. J Psychopharmacol 2016, 30: 1181-97

Elements of mystical-type experiences

MEQ 30 subscale items

- mystical
 - Unity of inside/outside, sacral, insight, lack of body, lack of border, part of something bigger, pure being, all one, *connectedness*
- Positive mood
 - peace, quiet, joy, bliss
- Transcendence of time/space
 - timeless
- Ineffability
 - Not to be described by words, awe, incomprehensible, amazing, humility, eternity, great

Acute experience predicted therapeutic efficacy



20 TRD patients, 10 and 25 mg **psilocybin**, peak experience: 5D-ASC; long-term effect: QIDS: Quick Inventory of Depressive Symptoms at 5 wks; response: 50% score reduction

Roseman et al. 2017 Front Pharmacol 8:974

Blissful State

- I enjoyed boundless pleasure
- I experienced a profound peace in myself
- I experienced an all-embracing love




Audio-Visual Synesthesiae

- Noises seemed to influence what I saw
- The shape of things seemed to change by sound and noises
- The colors of things seemd to be changed by sound and noises




Therapeutic Dimensions

- Meaningfulness
- Connectedness
- Reductions in defensiveness
- Acceptance / Helioscope
- Therapeutic Alliance
- Authenticity






Escitalopram reduced acute bad but not good drug effects of psilocybin



Anna Becker et al. Clin Pharmacol Ther 2022, 111:886-895

Escitalopram reduced anxiety but not the overall psychedelic response to psilocybin




Anna Becker et al. Clin Pharmacol Ther 2022, 111:886-895


Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication

Guy M. Goodwin¹[∞], Megan Croal¹, David Feifel², John R. Kelly³, Lindsey Marwood ¹, Sunil Mistry¹, Veronica O'Keane³, Stephanie Knatz Peck ⁴, Hollie Simmons¹, Claudia Sisa¹, Susan C. Stansfield¹, Joyce Tsai¹, Sam Williams¹ and Ekaterina Malievskaia¹


-19 patients with
depression with ongoing
SSRI treatment (mean
duration: 15 months)
25 mg of psilocybin add on
-Good therapeutic
response with no evidence



Neuropsychopharmacology; https://doi.org/10.1038/s41386-023-01648-7




LSD







Equivalent doses of different psychedelics



N=32, mean+SEM

LSD reduces amygdala BOLD response to fear






N=24, placebo-controlled administration of 100 µg LSD

Müller et al. 2017 Translational Psychiatry 7: e1084

LSD reduziert die Angst bei Patienten mit Angststörung rasch und anhaltend



 Rapid, long-lasting and significant reductions in anxiety at 16 weeks post-treatment in LSD group

Mean change from baseline difference = -16.2
 95% confidence interval [CI] = -27.8 to -4.5
 p = 0.007

- Clinical response (≥ 30% reduction of STAI-G scores):
 - **65%** in LSD group vs **9%** in placebo group


(*p* = 0.003)



Holze et al 2022 Biol Psych doi: 10.1016/j.biopsych.2022.08.025

Akute Wirkung korreliert mit Therapieeffekt

Positive Wirkung



Negative Wirkung

r = -0.67, *p* = 0.001**

r = 0.05, p = 0.8

n=20



Holze et al 2023 Biol Psych 93:215-223

Safety

Treatment-related events


- Untoward effects during treatment sessions
 - Nausea (10%)
 - Anxiety (7%)
 - Headache (2%)
- Serious adverse events
 - 1 x acute transient anxiety and delusions
 - Treated with lorazepam and olanzapine
 - \rightarrow second LSD dose reduced to 100 µg

Non-treatment-related events

- Adverse events during entire study duration:
 - Total: 229, similar in placebo and LSD condition
 - Most frequently: headache, nausea, dizziness, difficulty concentrating, common cold, insomnia
- Serious adverse events
 - Total: 8
 - Mostly due to underlying illness (cancer patients)

n=44





IV Bolus DMT 15 or 25 mg; IV Perfusion DMT 0.6 or 1 mg/min; data are mean and SEM in 30 subjects in for each dose; mean elimination half-life = 5-6 min (clinically-relevant early elimination; 0-15 min)

Vogt et al. 2023 Translat Psychiatry